Cargando…

Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats

Diosgenin (DIO) is a dietary and phytochemical steroidal saponin representing multiple activities. The present study investigated the protective effect of DIO on type II diabetes-associated nonalcoholic fatty liver disease (D-NAFLD). The rat model was established by high-fat diet and streptozotocin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Yujie, Li, Zhiman, Jin, Ruyi, Yao, Yanpeng, He, Silan, Lei, Min, Wang, Xin, Shi, Chao, Gao, Li, Peng, Xiaoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738614/ https://www.ncbi.nlm.nih.gov/pubmed/36501024 http://dx.doi.org/10.3390/nu14234994

Ejemplares similares

Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation
por: Wu, You, et al.
Publicado: (2021)

Diosgenin Targets CaMKK2 to Alleviate Type II Diabetic Nephropathy through Improving Autophagy, Mitophagy and Mitochondrial Dynamics
por: Zhong, Yujie, et al.
Publicado: (2023)

Diosgenin Inhibits ROS Generation by Modulating NOX4 and Mitochondrial Respiratory Chain and Suppresses Apoptosis in Diabetic Nephropathy
por: Zhong, Yujie, et al.
Publicado: (2023)

Raphani Semen (Raphanus sativus L.) Ameliorates Alcoholic Fatty Liver Disease by Regulating De Novo Lipogenesis
por: Park, Woo Yong, et al.
Publicado: (2021)

Granulocytic MDSC with Deficient CCR5 Alleviates Lipogenesis and Inflammation in Nonalcoholic Fatty Liver Disease
por: Liao, Tzu-Chieh, et al.
Publicado: (2022)

Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver
por: Fu, Xiaorong, et al.
Publicado: (2023)

The Role of Dietary Sugars and De novo Lipogenesis in Non-Alcoholic Fatty Liver Disease
por: Moore, J. Bernadette, et al.
Publicado: (2014)

Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
por: Paglialunga, Sabina, et al.
Publicado: (2016)

Fatty Liver Due to Increased de novo Lipogenesis: Alterations in the Hepatic Peroxisomal Proteome
por: Knebel, Birgit, et al.
Publicado: (2019)

Swietenine Alleviates Nonalcoholic Fatty Liver Disease in Diabetic Mice via Lipogenesis Inhibition and Antioxidant Mechanisms
por: Mak, Kit-Kay, et al.
Publicado: (2023)

Fasting hepatic de novo lipogenesis is not reliably assessed using circulating fatty acid markers
por: Rosqvist, Fredrik, et al.
Publicado: (2019)

Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance
por: Roumans, Kay H. M., et al.
Publicado: (2020)

Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis
por: Liu, Yan, et al.
Publicado: (2018)

Ruscogenin Ameliorates Experimental Nonalcoholic Steatohepatitis via Suppressing Lipogenesis and Inflammatory Pathway
por: Lu, Hung-Jen, et al.
Publicado: (2014)

Development of de novo nonalcoholic fatty liver disease following pancreatectomy
por: Patel, Vanisha, et al.
Publicado: (2023)

Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Baek, Jung-Hwan, et al.
Publicado: (2023)

Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis
por: Bielawiec, Patrycja, et al.
Publicado: (2023)

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
por: Lawitz, Eric J., et al.
Publicado: (2022)

Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice
por: Qian, Minyi, et al.
Publicado: (2019)

Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2
por: Qian, Xiaoli, et al.
Publicado: (2021)

Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues
por: Song, Ziyi, et al.
Publicado: (2018)

Role of mitochondrial quality control in the pathogenesis of nonalcoholic fatty liver disease
por: Li, Ruibing, et al.
Publicado: (2020)

Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study
por: Jacobs, Simone, et al.
Publicado: (2015)

Polyunsaturated Fatty Acids Stimulate De novo Lipogenesis and Improve Glucose Homeostasis during Refeeding with High Fat Diet
por: Crescenzo, Raffaella, et al.
Publicado: (2017)

Serial Biomarkers of De Novo Lipogenesis Fatty Acids and Incident Heart Failure in Older Adults: The Cardiovascular Health Study
por: Lee, Yujin, et al.
Publicado: (2020)

Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
por: Green, Charlotte J, et al.
Publicado: (2020)

Acetyl-CoA-mediated autoacetylation of fatty acid synthase as a metabolic switch of de novo lipogenesis in Drosophila
por: Miao, Ting, et al.
Publicado: (2022)

De Novo Lipogenesis-Related Monounsaturated Fatty Acids in the Blood Are Associated with Cardiovascular Risk Factors in HFpEF Patients
por: Bock, Matthias, et al.
Publicado: (2023)

Clitorin ameliorates western diet-induced hepatic steatosis by regulating lipogenesis and fatty acid oxidation in vivo and in vitro
por: Cominguez, Divina C., et al.
Publicado: (2022)

LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
por: Chen, Xue-Yang, et al.
Publicado: (2019)

S-Allyl cysteine improves nonalcoholic fatty liver disease in type 2 diabetes Otsuka Long-Evans Tokushima Fatty rats via regulation of hepatic lipogenesis and glucose metabolism
por: Takemura, Shigekazu, et al.
Publicado: (2013)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease
por: Chimienti, Guglielmina, et al.
Publicado: (2021)

Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
por: ter Horst, Kasper W., et al.
Publicado: (2017)

Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats
por: Li, Donghao, et al.
Publicado: (2017)

Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats
por: Zhou, Yuan, et al.
Publicado: (2022)

Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress
por: Ji, Yun, et al.
Publicado: (2019)

Myeloid-specific blockade of Notch signaling ameliorates nonalcoholic fatty liver disease in mice
por: Ding, Jian, et al.
Publicado: (2023)

Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis
por: Yao, Min, et al.
Publicado: (2023)

The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Ndakotsu, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uh7gsfs0htofnglnvam9ub66r1